Benutzer: Gast  Login
Dokumenttyp:
journal article 
Autor(en):
Bitzer, Michael; Horger, Marius; Giannini, Edoardo G; Ganten, Tom M; Wörns, Marcus A; Siveke, Jens T; Dollinger, Matthias M; Gerken, Guido; Scheulen, Max E; Wege, Henning; Zagonel, Vittorina; Cillo, Umberto; Trevisani, Franco; Santoro, Armando; Montesarchio, Vincenzo; Malek, Nisar P; Holzapfel, Julia; Herz, Thomas; Ammendola, Astrid S; Pegoraro, Stefano; Hauns, Bernhard; Mais, Anna; Lauer, Ulrich M; Henning, Stefan W; Hentsch, Bernd 
Titel:
Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study. 
Abstract:
No established therapies for patients with hepatocellular carcinoma (HCC) and progression on first-line sorafenib treatment currently exist. This phase I/II trial investigated safety, pharmacokinetics and potential biomarkers of the histone deacetylase inhibitor resminostat and a combination therapy with resminostat and sorafenib.Patients with HCC and radiologically confirmed progression on sorafenib were treated in an exploratory, multi-center, open-label, uncontrolled, non-randomized, parallel...    »
 
Zeitschriftentitel:
J Hepatol 
Jahr:
2016 
Band / Volume:
65 
Heft / Issue:
Seitenangaben Beitrag:
280-8 
Sprache:
eng 
Print-ISSN:
0168-8278 
TUM Einrichtung:
II. Medizinische Klinik und Poliklinik